Drugs, CervicalCheck and government inequity

Of course cancer patients want to access the new, ‘wonder drugs’, but the money would have to be taken from other healthcare services

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
25th November, 2018

The government made the decision to reimburse experimental drugs for women affected by the CervicalCheck debacle last May.

It bypassed the approvals process that all drugs usually go through - namely a cost-effectiveness assessment by the National Centre for Pharmacoeconomics (NCPE).

It was an unprecedented move - and a very ill-advised one.

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Private rental sector remains strong despite Covid-19

How the programme for government will shape housing

Insight Niall Byrne 8 months ago

Comment: US must defuse Covid-19’s ticking time bomb of debt

Insight Todd G Buchholz 8 months ago

Comment: The recovery will be more U than V-shaped

Insight Larry Hatheway 8 months ago